Conditions: Tumors
Keywords: Advanced Solid Tumours phase II Hypertension RECENTIN
Allocation: RANDOMIZED | Intervention model: FACTORIAL
Enrollment: 119
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.

Detailed description:

Arms:
arm 1: 30 mg AZD2171 arm 2: 45 mg AZD2171

Interventions: intervention 1: AZD2171
Intervention descriptions: intervention 1: 30 mg \& 45 mg oral tablet

Protocol document: